Silver Book Fact

Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.

Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill, Jerrold W., Robert Futterman, Vera Mastey, and Howard Fillit
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • A new study reports that using optogenetics, stimulating specific brain cells using light, may provide better results for Parkinson’s patients than traditional deep brain stimulation because of the ability to…  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…